Sign in

    Michael Hop

    Research Analyst at Baird

    No publicly available information could be found for Michael Hop as an analyst at Baird. Despite a thorough search for both LinkedIn and professional profiles, there is no evidence of an individual by this name holding an analyst or similar position at Baird or covering equities for the firm. There are no documented coverage specialties, performance metrics, professional credentials, or career timeline available for Michael Hop in reputable investor databases or on Baird’s official research team listing.

    Michael Hop's questions to Cigna (CI) leadership

    Michael Hop's questions to Cigna (CI) leadership • Q3 2024

    Question

    Michael Hop asked for more detail on the 2025 headwinds and tailwinds, the adoption trend for the HUMIRA biosimilar, and whether Evernorth is now in a sustainable high single-digit growth paradigm.

    Answer

    CFO Brian Evanko detailed the tailwinds (biosimilars, PBS client advancements, MA sale proceeds) and headwinds (loss of VillageMD dividend, stranded overhead, growth investments). Evernorth CEO Eric Palmer reported that HUMIRA biosimilar adoption among eligible patients grew from 20% in July to 33% for Q3. He reiterated Evernorth's long-term growth target of 5-8%, stating it reflects these dynamics rather than declaring a 'new normal'.

    Ask Fintool Equity Research AI